Related references
Note: Only part of the references are listed.Phase 2 Study of Dabrafenib Plus Trametinib in Patients With BRAF V600E-Mutant Metastatic NSCLC
David Planchard et al.
JOURNAL OF THORACIC ONCOLOGY (2022)
Durable Response to the Combination of Atezolizumab With Platinum-Based Chemotherapy in an Untreated Non-Smoking Lung Adenocarcinoma Patient With BRAF V600E Mutation: A Case Report
Xiaomin Niu et al.
FRONTIERS IN ONCOLOGY (2021)
Vemurafenib in non-small-cell lung cancer patients with BRAFV600 and BRAFnonV600 mutations
J. Mazieres et al.
ANNALS OF ONCOLOGY (2020)
Clinical activity of programmed cell death 1 (PD-1) blockade in never, light, and heavy smokers with non-small-cell lung cancer and PD-L1 expression >= 50%
J. F. Gainor et al.
ANNALS OF ONCOLOGY (2020)
Phase I/II Trial of Immunotherapy With Durvalumab and Tremelimumab With Continuous or Intermittent MEK Inhibitor Selumetinib in NSCLC: Early Trial Report
Pierre-Olivier Gaudreau et al.
CLINICAL LUNG CANCER (2020)
Efficacy and Safety of Anti-PD-1 Immunotherapy in Patients With Advanced NSCLC With BRAF, HER2, or MET Mutations or RET Translocation: GFPC 01-2018
Florian Guisier et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors
Jayesh Desai et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Phase Ib study of LXH254+LTT462 in patients with KRAS- or BRAF-mutant NSCLC
J. Wolf et al.
ANNALS OF ONCOLOGY (2020)
Multiple Biomarker Testing Tissue Consumption and Completion Rates With Single-gene Tests and Investigational Use of Oncomine Dx Target Test for Advanced Non-Small-cell Lung Cancer: A Single-center Analysis
Tiffany M. Yu et al.
CLINICAL LUNG CANCER (2019)
Phase Ib study of atezolizumab combined with cobimetinib in patients with solid tumors
M. D. Hellmann et al.
ANNALS OF ONCOLOGY (2019)
BRAF Mutant NSCLC and Immune Checkpoint Inhibitors: Results From a Real-World Experience
Karim Rihawi et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry
J. Mazieres et al.
ANNALS OF ONCOLOGY (2019)
Pulsatile MEK Inhibition Improves Anti-tumor Immunity and T Cell Function in Murine Kras Mutant Lung Cancer
Hyejin Choi et al.
CELL REPORTS (2019)
Clinical outcomes of non-small-cell lung cancer patients with BRAF mutations: results from the French Cooperative Thoracic Intergroup biomarkers France study
Sebastien Couraud et al.
EUROPEAN JOURNAL OF CANCER (2019)
Hairy cell leukemia: 2020 update on diagnosis, risk stratification, and treatment
Elsa Maitre et al.
AMERICAN JOURNAL OF HEMATOLOGY (2019)
Molecular Characteristics, Immunophenotype, and Immune Checkpoint Inhibitor Response in BRAF Non-V600 Mutant Lung Cancers
M. Offin et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Impact of BRAF Mutation Class on Disease Characteristics and Clinical Outcomes in BRAF-mutant Lung Cancer
Ibiayi Dagogo-Jack et al.
CLINICAL CANCER RESEARCH (2019)
BRAF internal deletions and resistance to BRAF/MEK inhibitor therapy
Douglas B. Johnson et al.
PIGMENT CELL & MELANOMA RESEARCH (2018)
Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology
Neal I. Lindeman et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2018)
BRAF in non-small cell lung cancer (NSCLC): Pickaxing another brick in the wall
Alessandro Leonetti et al.
CANCER TREATMENT REVIEWS (2018)
Molecular and Immune Biomarker Testing in Squamous-Cell Lung Cancer: Effect of Current and Future Therapies and Technologies
Fred R. Hirsch et al.
CLINICAL LUNG CANCER (2018)
BRAF Adds an Additional Piece of the Puzzle to Precision Oncology-Based Treatment Strategies in Lung Cancer
David Planchard et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2018)
Characteristics and Predictive Value of PD-L1 Status in Real-World Non-Small Cell Lung Cancer Patients
Jeng-Sen Tseng et al.
JOURNAL OF IMMUNOTHERAPY (2018)
An Acquired NRAS Q61K Mutation in BRAF V600E-Mutant Lung Adenocarcinoma Resistant to Dabrafenib Plus Trametinib
Daniel L. Abravanel et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point Inhibitors
Elizabeth Dudnik et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations
Matthew Dankner et al.
ONCOGENE (2018)
Association between PD-L1 expression and driver gene status in non-small-cell lung cancer: a meta-analysis
Bo Lan et al.
Oncotarget (2018)
KRAS Mutation as a Resistance Mechanism to BRAF/MEK Inhibition in NSCLC
Maarten Niemantsverdriet et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Lung cancer in never smokers-the East Asian experience
Fei Zhou et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2018)
The mitogen-activated protein kinase pathway in melanoma part I - Activation and primary resistance mechanisms to BRAF inhibition
Teresa Amaral et al.
EUROPEAN JOURNAL OF CANCER (2017)
Strategies for Overcoming Resistance in Tumours Harboring BRAF Mutations
Nourah Mohammad Obaid et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial
David Planchard et al.
LANCET ONCOLOGY (2017)
Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS
Zhan Yao et al.
NATURE (2017)
Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
Ahmet Zehir et al.
NATURE MEDICINE (2017)
Clinicopathologic characteristics and outcomes of Chinese patients with non-small-cell lung cancer and BRAF mutation
Xi Ding et al.
CANCER MEDICINE (2017)
Clinical profiles and trend analysis of newly diagnosed lung cancer in a tertiary care hospital of East China during 2011-2015
Pingli Wang et al.
JOURNAL OF THORACIC DISEASE (2017)
The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment
Edmund Poon et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2017)
The distribution of BRAF gene fusions in solid tumors and response to targeted therapy
Jeffrey S. Ross et al.
INTERNATIONAL JOURNAL OF CANCER (2016)
Template for Reporting Results of Biomarker Testing of Specimens From Patients With Melanoma
Lynette M. Sholl et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2016)
Cancer Statistics in China, 2015
Wanqing Chen et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2016)
Activation Mechanism of Oncogenic Deletion Mutations in BRAF, EGFR, and HER2
Scott A. Foster et al.
CANCER CELL (2016)
BRAF mutations in non-small cell lung cancer: has finally Janus opened the door?
Rafael Caparica et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2016)
Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma
Ching-Yao Yang et al.
EUROPEAN JOURNAL OF CANCER (2016)
Programmed death-ligand 1 expression associated with molecular characteristics in surgically resected lung adenocarcinoma
Zhengbo Song et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2016)
Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)
Fabrice Barlesi et al.
LANCET (2016)
Dabrafenib in patients with BRAFV600E-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial
David Planchard et al.
LANCET ONCOLOGY (2016)
Clinical characteristics and outcome of patients with lung cancer harboring BRAF mutations
Claire Tissot et al.
LUNG CANCER (2016)
Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120
Shih-Hsun Chen et al.
CANCER DISCOVERY (2016)
BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition
Zhan Yao et al.
CANCER CELL (2015)
BRAF Mutation and Thyroid Cancer Recurrence
Mark Yarchoan et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Targeted Therapy for Patients with BRAF-Mutant Lung Cancer Results from the European EURAF Cohort
Oliver Gautschi et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Monotherapy Administration of Sorafenib in Patients With Non-Small Cell Lung Cancer (MISSION) Trial A Phase III, Multicenter, Placebo-Controlled Trial of Sorafenib in Patients with Relapsed or Refractory Predominantly Nonsquamous Non-Small-Cell Lung Cancer after 2 or 3 Previous Treatment Regimens
Luis Paz-Ares et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
David M. Hyman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation profiling from 5125 Chinese cohorts
S. Li et al.
BRITISH JOURNAL OF CANCER (2014)
Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes
Ching-Yao Yang et al.
EUROPEAN JOURNAL OF CANCER (2014)
Molecular pathology of malignant melanoma: changing the clinical practice paradigm toward a personalized approach
Joshua R. Bradish et al.
HUMAN PATHOLOGY (2014)
Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs
Mark G. Kris et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
Clinical Characteristics and Course of 63 Patients with BRAF Mutant Lung Cancers
Anya M. Litvak et al.
JOURNAL OF THORACIC ONCOLOGY (2014)
Comprehensive molecular profiling of lung adenocarcinoma
Eric A. Collisson et al.
NATURE (2014)
Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy
Hubing Shi et al.
CANCER DISCOVERY (2014)
Diagnostic value of immunohistochemistry for the detection of the BRAFV600E mutation in primary lung adenocarcinoma Caucasian patients
M. Ilie et al.
ANNALS OF ONCOLOGY (2013)
Tumor Genetic Analyses of Patients with Metastatic Melanoma Treated with the BRAF Inhibitor Dabrafenib (GSK2118436)
Katherine L. Nathanson et al.
CLINICAL CANCER RESEARCH (2013)
Clinical, Pathologic, and Biologic Features Associated with BRAF Mutations in Non-Small Cell Lung Cancer
Stephanie Cardarella et al.
CLINICAL CANCER RESEARCH (2013)
Microsatellite Instability and BRAF Mutation Testing in Colorectal Cancer Prognostication
Paul Lochhead et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2013)
Molecular Characterization of Acquired Resistance to the BRAF Inhibitor Dabrafenib in a Patient with BRAF-Mutant Non-Small-Cell Lung Cancer
Charles M. Rudin et al.
JOURNAL OF THORACIC ONCOLOGY (2013)
Usefulness of immunohistochemistry for the detection of the BRAF V600E mutation in Japanese lung adenocarcinoma
Hidefumi Sasaki et al.
LUNG CANCER (2013)
Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma
David T. W. Jones et al.
NATURE GENETICS (2013)
NRAS mutation status is an independent prognostic factor in metastatic melanoma
John A. Jakob et al.
CANCER (2012)
A Double-Blind Randomized Discontinuation Phase-II Study of Sorafenib (BAY 43-9006) in Previously Treated Non-Small-Cell Lung Cancer Patients Eastern Cooperative Oncology Group Study E2501
Heather A. Wakelee et al.
JOURNAL OF THORACIC ONCOLOGY (2012)
Resistance to BRAF Inhibitors: Unraveling Mechanisms and Future Treatment Options
Jessie Villanueva et al.
CANCER RESEARCH (2011)
Clinical Features and Outcome of Patients With Non-Small-Cell Lung Cancer Harboring BRAF Mutations
Antonio Marchetti et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Clinical Characteristics of Patients With Lung Adenocarcinomas Harboring BRAF Mutations
Paul K. Paik et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
The Use of Immunohistochemistry for Biomarker Assessment-Can It Compete with Other Technologies?
Robert W. Dunstan et al.
TOXICOLOGIC PATHOLOGY (2011)
Clinical Impact of the Detection of BRAF Mutations in Thyroid Pathology: Potential Usefulness as Diagnostic, Prognostic and Theragnostic Applications
Sandra Lassalle et al.
CURRENT MEDICINAL CHEMISTRY (2010)
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
Cory M. Johannessen et al.
NATURE (2010)
PI3K Pathway Activation Mediates Resistance to MEK Inhibitors in KRAS Mutant Cancers
Susan Wee et al.
CANCER RESEARCH (2009)
Phase II, Multicenter, Uncontrolled Trial of Single-Agent Sorafenib in Patients With Relapsed or Refractory, Advanced Non-Small-Cell Lung Cancer
George R. Blumenschein et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Tandem Duplication Producing a Novel Oncogenic BRAF Fusion Gene Defines the Majority of Pilocytic Astrocytomas
David T. W. Jones et al.
CANCER RESEARCH (2008)
Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer
Amy J. French et al.
CLINICAL CANCER RESEARCH (2008)
Sorafenib in lung cancer: Clinical developments and future directions
George Blumenschein
JOURNAL OF THORACIC ONCOLOGY (2008)
Sorafenib is efficacious and tolerated in combination with cytotoxic or cytostatic agents in preclinical models of human non-small cell lung carcinoma
Christopher A. Carter et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2007)
Role of Raf kinase in cancer: Therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway
Jared A. Gollob et al.
SEMINARS IN ONCOLOGY (2006)
Distinct sets of genetic alterations in melanoma
JA Curtin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Raf: A strategic target for therapeutic development against cancer
M Beeram et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
The RAF proteins take centre stage
C Wellbrock et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2004)
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
SM Wilhelm et al.
CANCER RESEARCH (2004)
Mutations of the BRAF gene in human cancer
H Davies et al.
NATURE (2002)
Share Paper
